(NASDAQ: JSPR) Jasper Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 27.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.33%.
Jasper Therapeutics's earnings in 2025 is -$90,922,000.On average, 11 Wall Street analysts forecast JSPR's earnings for 2025 to be -$82,256,488, with the lowest JSPR earnings forecast at -$94,932,462, and the highest JSPR earnings forecast at -$69,458,614. On average, 11 Wall Street analysts forecast JSPR's earnings for 2026 to be -$48,686,856, with the lowest JSPR earnings forecast at -$104,807,986, and the highest JSPR earnings forecast at -$22,868,438.
In 2027, JSPR is forecast to generate -$36,638,261 in earnings, with the lowest earnings forecast at -$54,952,515 and the highest earnings forecast at -$19,455,238.